News and Trends 18 Aug 2017 Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes A team of Swedish researchers has published today an interactive map for the visualization of the effects of individual cancer genes that supports personalized medicine. The new Pathology Atlas is an open access online resource containing genomic data from over 8,000 patients across 17 major cancer types. By typing in the name of any gene […] August 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2017 Biosimilars Struggle to Substitute Brand-Name Drugs Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs. A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from Pfizer that imitates Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Despite bringing a price reduction […] August 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2017 And the Winner for the BioPharm America 2017 FREE Ticket Giveaway is… Three weeks ago, on July 26th, we published the free ticket giveaway for the BioPharm America conference in Boston, Massachusetts, which is taking place from September 26th – 27th, 2017! Today, our randomizer selected Susanna Bächle from Addgene as the WINNER! Congratulations! Susanna was selected randomly from a long list of entries, so thank you to […] August 16, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2017 UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer Mundipharma has acquired the rights to CAP7.1, a drug that could bring the first alternative to surgery and chemo for patients with biliary tract cancer. Cambridge-based Mundipharma has paid $250M (€212M) to the German biotech CellAct in exchange for the worldwide development, commercialization and manufacturing rights to CAP7.1. The candidate is a prodrug that, when metabolized, […] August 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2017 Cancer Research UK Teams Up with London Startup in Immuno-oncology Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase […] August 11, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 10 Aug 2017 Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat patients with idiopathic pulmonary fibrosis (IPF). The median survival is 2 to 5 years after […] August 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 9 Aug 2017 UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2017 Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2017 Demo Day: Meet the Latest Generation of Synbio Startups from RebelBio The RebelBio startups of 2017 reach a major milestone as 15 young companies came forward to explain their ideas, science and how they are selling them. A mere 3 months after the 15 chosen projects for the RebelBio accelerator went off to the labs to refine their prototypes, Demo Day arrived last week on July […] August 4, 2017 - 6 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2017 Designer Babies in Europe: German Merck Set to Receive CRISPR Patent Merck KGaA has received a Notice of Intention to Grant from the European Patent Office that its CRISPR patent will cover genomic integration. Everyone in biotech is gunning for a piece of the CRISPR pie, and German Merck will likely become the next company to acquire IP, adding to the pile it began building in 2012. […] August 3, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2017 Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy TC Biopharm has just received the largest award of its kind to develop allogeneic gamma-delta T cell therapies for various cancers. Based in Glasgow, TC Biopharm was just selected to receive €4M from Horizon 2020 for its “off-the-shelf” gamma-delta T cell program. This grant brings the company’s fundraising total to €25M, and it’s the largest any UK […] August 2, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2017 French Biotech May Save Toddlers from Life-Threatening Peanut Allergy The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies’ Phase IIb results of its peanut allergy therapy, Viaskin Peanut, were one of 2016’s biggest clinical success stories when it successfully desensitized children to obviate life-threatening allergies. A trial in children between the ages […] August 2, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email